Hi [[ session.user.profile.firstName ]]

Life Sciences

  • When small becomes big: orphan medicines, advances, access and affordability
    When small becomes big: orphan medicines, advances, access and affordability Alastair Kent OBE, Malcolm Qualie, Sheela Upadhyaya, Sarah Rickwood, Moderated by Paul Tunnah Recorded: Apr 10 2017 75 mins
    Over the past few years there has been a shift in the European pharmaceutical market landscape, with a rise in specialty medicines for diseases with narrow patient populations. Indeed, QuintilesIMS forecasts that, between 2013 and 2018, 94% of list price value growth will be in specialty medicines – with orphan drugs at the forefront of this trend.
    On 10 April 2017, QuintilesIMS, in partnership with pharmaphorum presents a unique digital debate, bringing together a panel of senior industry experts, including participants from NICE, NHS England and Genetic Alliance UK to explore the pillars of commercial success for orphan drugs in Europe in the context of changes in reimbursement processes and broader future challenges, like Brexit.
  • Enabling CAR-T Screening in 3D Tumor Spheroids
    Enabling CAR-T Screening in 3D Tumor Spheroids Van Dang, D.V.M., Ph.D., Abhi Saharia, Ph. D., and Audrey Bergeron, Applications Scientist Recorded: Mar 30 2017 62 mins
    Webinar Date & Time: Mar 30 2017 12:00 p.m. EST

    Chimeric antigen receptor (CAR)-T cells, which are engineered to recognize target cell surface antigens expressed on tumor cells, have shown promise to affect complete remission in patients with B-cell malignancies. However, applying this approach to target solid tumors has resulted in adverse effects in clinical studies. Methods for testing different models of CAR-T cells in vitro can provide further insight into viable antigen targets. Historically, two-dimensional (2D) cell culture models have been used in drug discovery. However, more elaborate, three-dimensional (3D) cell culture models better mimic the in vivo tumor microenvironment and help bridge the gap between in vitro studies and clinical outcomes.

    In this special joint webinar, panelists from ProMab Biotechnologies, DiscoverX, and Corning Life Sciences will present data on a high-throughput, easy-to-use, highly reproducible method for screening CAR-T cells in a 3D cell culture model by combining various technologies.


    Speakers:
    Van Dang, D.V.M., Ph.D.
    Scientist and coordinator for CAR-T research
    ProMab Biotechnologies, Inc.

    Abhi Saharia, Ph. D.
    Director, Cell-based Assays and Biologics
    DiscoverX

    Audrey Bergeron
    Applications Scientist
    Corning Life Sciences
  • Accelerating NGS Workloads with Scientific Cloud Computing
    Accelerating NGS Workloads with Scientific Cloud Computing Scott Jeschonek, Director of Cloud Products, Avere Systems Recorded: Mar 29 2017 46 mins
    Next-generation sequencing (NGS) technology has brought an influx of large-scale data and ever-growing demands for compute, resulting in a challenge for those in science informatics. To overcome these issues, laboratories need to be able to support researchers while managing data and the infrastructure needed to deliver mission-critical results and ultimately, positive patient outcomes.

    At the NGS Data Analysis and Informatics Conference in February, attendees spoke about these challenges at length. This webinar, built from content shared at the event, will review potential approaches to cost-effective data growth using cloud compute and storage. Moving genomics workloads to the cloud can provide scale and affordability, while optimizing investments in existing resources. Adding that ability to allow researchers to easily collaborate while reducing latencies to these resources is pertinent to usability.

    In this webinar, you’ll learn how to:
    - Increase computation potential
    - Optimize your physical infrastructure
    - Diagram common use cases to meet specific research goals
    - Increase flexibility by limiting data gravity
  • Biosimilars - A Network perspective
    Biosimilars - A Network perspective Divya Chadha Manek Recorded: Mar 29 2017 15 mins
    A biosimilar medicine is a biological medicine which is highly similar to another biological medicine already licensed for use. It is a biological medicine which has been shown not to have any clinically meaningful differences from the originator biological medicine in terms of quality, safety and efficacy.
  • Unlocking the value of pharmacists to reach the right patients and consumers
    Unlocking the value of pharmacists to reach the right patients and consumers Pierre-Yves Boisvert, Paulien Schul, Nina Felton and Andrew McConaghie Recorded: Mar 29 2017 70 mins
    Pharmacists are highly trained healthcare professionals who have a deep understanding of medicines and daily contact with patients and consumers. This puts them in a unique position in terms of being able to maximise the benefits that patients get from their medicines – however, healthcare systems and pharmaceutical companies frequently overlook this potential.
    Pharmacists are especially well placed to help patients with multiple long-term conditions manage their health and medications, and pharmacist-led interventions have been shown to have a very significant impact on compliance and disease management in the community.
    We present a webinar debate in which our expert panel will discuss how pharmaceutical companies can work in collaboration with pharmacists in Europe to help patients make the most of their medicines, help generate data to prove the value of these interventions, and above all get the right medicine to the right patients and consumers.
    Join us and the PHOENIX group as we look at the practical steps needed to make this a reality. Key topics to be discussed include:
    •The challenges of identifying the right patient population across European markets
    •Understanding how pharmacists can play a greater role in patient care, e.g. improved adherence and outcomes
    •How optimum use of pharmacy level information can contribute to providing ‘real world’ evidence of treatments
  • NIHR Clinical Research Network support for Biosimilars clinical trials
    NIHR Clinical Research Network support for Biosimilars clinical trials Dr Sonya Abraham, Consultant Research Physician and Rheumatologist Recorded: Mar 29 2017 16 mins
    This presentation will discuss NIHR Clinical Research Network support for Biosimilar clinical trials. It begins with a background to biosimilars and the changing landscape in their drug development and regulatory pathways. It then focuses on the opportunities that the NHS via the NIHR CRNs can engage in biosimilar clinical trials across therapeutic indications.
  • Analytical Strategies for Comparability in Bioprocess Development
    Analytical Strategies for Comparability in Bioprocess Development Christine P. Chan, Ph.D & Joe Barco, Ph.D. Recorded: Mar 28 2017 71 mins
    Comparability exercises are commonly required at certain milestones during drug development as well as after product registration when changes are implemented into the manufacturing process. The goal is to evaluate if the product remains highly similar (not necessarily identical) before and after the change in terms of quality and stability and have no adverse impact on safety and efficacy predicted for the patients. This assessment requires product-specific knowledge gathered through drug development, taking a totality-of-evidence approach. The different levels of information are obtained from analytical studies for characterization of the molecule, animal studies for toxicity, pharmacokinetics and pharmacodynamics for pharmacological activities, and clinical studies for safety/tolerability, immunogenicity and efficacy. This Webinar discusses strategies and considerations for analytical characterization of protein structure and function which forms the foundation of the comparability demonstration.

    Sponsored by Unchained Labs

    Presentation Title: Limber up your lab with better tools for comparing biologics

    There’s no magic bullet when it comes to characterizing a protein by structure or function. Specific tests may work for one molecule but not the next. Instrumentation that provides a high degree of flexibility, balanced with low sample consumption and faster time to result, is crucial to keep up with ever changing laboratory needs. Unchained Labs puts biologics characterization front and center for our instrumentation development. We will discuss how our instruments let researchers be more flexible and efficient, while also providing clear data to help make comparability assessments.
  • New Ways to Boost Sales Productivity in 2017 [Panel Discussion]
    New Ways to Boost Sales Productivity in 2017 [Panel Discussion] Gerhard Gschwandtner (Moderator); Anthony Iannarino, Teja Vora Recorded: Mar 21 2017 57 mins
    A new year, a new strategy, and new tools for winning sales! Join us for this webinar to get the inspiration and tips you need to set your intention to make 2017 the year of hustle, value creation, and digital transformation. Bestselling author and award-winning blogger, Anthony Iannarino, will share his top sales insights in this interactive webinar that welcomes audience participation and questions.

    Key takeaways for this webinar will include
    - The year of hustle. Learn how to create the right mindset and skillset to stay a step ahead of your competition.
    - The year of value creation. Discover how top performers focus on value creation - Anthony will share his secret sauce for winning more sales.
    - The year of digital transformation. Learn how to avoid time-wasting technology and social media traps and instead leverage the best tools to work 100 percent smarter, not harder.

    Moderator: Gerhard Gschwandtner, Founder & CEO, Selling Power
    Speakers: Anthony Iannarino, Bestselling Author and Sales Leader
    Teja Vora, Director of Marketing, DocuSign
  • Sanger Arrayed CRISPR Screening in partnership with Evotec
    Sanger Arrayed CRISPR Screening in partnership with Evotec Dr. Hauke Cornils-Res Scientist, Evotec & Shawn Shafer-Dir. Advance Genomics Life Science Business of Merck KGaA, Darmstadt, Recorded: Mar 16 2017 50 mins
    CRISPR Cas9 nucleases have revolutionized the field of gene editing and high-throughput lentiviral screens continue to hold ever-increasing promise for both basic research and development of future therapies to benefit human health. Even with such powerful technologies at hand, researchers new to the field may find the screening of multiple targets to be challenging and time-consuming. This webinar discusses the Evotec partnership with Life Science Business of Merck KGaA, Darmstadt, Germany and the screening services for drug discovery.
  • Approval and access: Overcoming the final hurdle of drug development
    Approval and access: Overcoming the final hurdle of drug development Professor Luca Pani, University of Miami, Angelika Joos,MSD (Europe) Inc. Ana Palma, Sobi, Belgium Recorded: Mar 10 2017 61 mins
    2017 is once again a year of significant change for pharma market access in Europe, with affordability on the agenda for almost every country in the region. There is a move toward greater collaboration in health technology assessment and more transparency between countries for pricing, therapeutic protocols and and details of negotiations with drug manufacturers. We also see member states working to understand the process of enabling cost-effective patient access to personalised and high-cost treatments, such as new oncology combination therapies, antibiotics and stem cell therapies, which offer the promise of efficacy in key disease areas.

    With market access being referred to as the “fourth hurdle” in drug development (beyond efficacy, safety and quality), it is vital that the requirements for both approval and access are addressed early in the process. Parallel scientific advice from HTA bodies and regulators is increasing to deliver tangible and successful strategies, but is the process smooth enough to overcome the challenges from both sides?

    pharmaphorum in partnership with DIA will be hosting an expert panel debating the best way forward for life sciences companies, payers and providers in this emerging European market access paradigm.

    Join our webinar to hear from experts in industry and healthcare discussing the challenges and solutions of access in the changing European market.
    Topics up for discussion include:
    •Integrating HTA and regulatory strategy – the best way forward
    •Regional variation and implication – how to efficiently and effectively navigate EU market access
    •Proving value – how to leverage real world evidence to meet increasing demands for observational data
    •Future proofing market access – how to improve upon evidence generation and use technology effectively and competitively
  • Surfaces for Organoid Culture
    Surfaces for Organoid Culture Nitin Kulkarni, Ph.D. Recorded: Feb 23 2017 50 mins
    3D culture is gaining pivotal importance for attaining in vivo-like conditions in a dish to study developmental cues as well as therapeutic possibilities. Organoid development promises to be one of the most important research tools in the near future. This presentation will cover:

    • Methodologies used in organoid culture
    • Matrices for growing organoids
    • Recovery of organoids for downstream applications

    Speaker Bio:

    Dr. Nitin Kulkarni is a member of the Scientific Support team at Corning Life Sciences. He has a Ph.D. in Biology and has worked on engineering transgenic mouse models for autoimmune diseases during his post-doctoral research at the Beth Israel Deaconess Medical Center in Boston, MA.
    In his current role, he supports researchers with applications related to cell culture including advanced surfaces and extracellular matrices, genomics, drug discovery and bioprocesses.
  • Subvisible Particle Identification & Characterisation by Multi-Technique Methods
    Subvisible Particle Identification & Characterisation by Multi-Technique Methods Dr Jonas Hoeg Thygesen & Colin Merrifield Recorded: Feb 23 2017 61 mins
    Observable foreign and particulate matter has for a long time been recognized as a critical quality attribute for production of injectable protein formulations. Recently, a focus shift towards these particles and even smaller particles (particulate matter or subvisible particles) has been seen from the pharmaceutical industry, academia and the different regulatory bodies. Two of the central documents in this context are:

    1. The FDA Guidance for Industry on Immunogenicity Assessment for Therapeutic Protein Products1 and

    2. United States Pharmacopia Chapter 2
  • How do you Decide Whom to Biopsy for Prostate Cancer?
    How do you Decide Whom to Biopsy for Prostate Cancer? Dr. E. David Crawford Recorded: Feb 17 2017 61 mins
    In our webinar, Identifying Men with Prostate Cancer—The Role of phi and Other Biomarkers, Dr. E. David Crawford will discuss key issues that challenge a physician's ability to make informed decisions regarding whom to biopsy for prostate cancer. After the webinar, you will be able to:

    • Understand the historical perspective and controversy regarding prostate-specific antigen (PSA) screening

    • Improve your interpretation of a PSA result

    • Use biomarkers, such as Prostate Health Index (phi), to reduce negative biopsies and have more confidence in the decision to biopsy

    • Understand how the phi score, combined with family and patient history, can determine patient management decisions

    Dr. Crawford is an internationally renowned urologist and distinguished endowed professor of surgery, urology and radiation oncology. He also serves as the head of the section of urologic oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
  • Challenges and Successes in Externalization of the ADC Supply Chain
    Challenges and Successes in Externalization of the ADC Supply Chain Firelli Alonso, Ph.D. Recorded: Feb 14 2017 74 mins
    Sourcing for the manufacture and control of Antibody-Drug Conjugates (ADCs) used in clinical trials requires strategic planning, establishment of a specialized support network, and execution of several interdependent tasks. ADCs are complex molecules, a fusion of a biological, the monoclonal antibody (mAb), and of small molecules, the linker and the toxic payload. Facilities of acceptable standards for the handling of high potency materials need to be engaged, and there is a limited supply currently. This is further complicated by the fact that there is not one contract facility that has fully integrated services, a “one-stop shop” capable of mAb production, linker and/or payload synthesis, conjugation of mAb to linker-payload to make the Drug Substance, and finally, formulation of the ADC to make the Drug Product. Strategizing the best outsourcing practices for producing and testing ADCs, and establishing guiding principles for externalization to ensure the selection of the right CMOs for ADC outsourcing and technology transfer, will be further discussed.
  • Common Challenges in Evaluating the Reproductive System in Nonclinical
    Common Challenges in Evaluating the Reproductive System in Nonclinical Justin Vidal, PhD, DVM, DACVP Recorded: Feb 9 2017 53 mins
    According to the ICH Harmonised Tripartite Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2), both men and women of child bearing potential (WoCBP) can be included in Phase I and II trials before the conduct of the male and female nonclinical fertility studies, since an evaluation of the male and female reproductive organs is performed in the repeat-dose toxicity studies. As such, much of the early assessment of potential test article-related effects on the reproductive system falls on the nonclinical toxicologic pathologist. This requires the pathologist to have a have a sound understanding of spermatogenesis, stage-aware evaluation of the testis, estrous and menstrual cyclicity, and normal physiology and endocrinology in order to carefully and thoroughly evaluate potential xenobiotic-related effects on the reproductive system. However, even with the most thorough pathology assessment, the design and conduct of nonclinical general toxicity studies can greatly impact the pathologist’s evaluation of the reproductive system. Commonly encountered challenges include age (onset of puberty and reproductive senescence), body weight changes and systemic toxicity, husbandry practices, strain differences, small sample size (non-rodents), and even histologic sectioning patterns.
  • Rescheduled: Multicellular Tumor Spheroids in HTS: New Assays
    Rescheduled: Multicellular Tumor Spheroids in HTS: New Assays Wojciech Senkowski Recorded: Feb 1 2017 50 mins
    Three-dimensional cell cultures, and multicellular tumor spheroids in (MCTS) in particular, have recently become a widely used tool for preclinical anticancer drug testing in high-throughput screening (HTS) setup. However, even though MCTS have been applied for HTS, their use has been limited to simple assays, such as assessing cell viability or inhibition of growth.

    This webinar will cover new approaches to MCTS-based HTS. It will present a new, robust viability assay, well-suited for HTS and based on green fluorescent protein (GFP) used as a surrogate marker of spheroid viability. It will also review a first-ever approach to obtain information-rich transcriptomic data from drug-treated MCTS on a large scale. In addition, the presenter will demonstrate how this novel platform resulted in the identification of previously unrecognized, context-dependent drug responses of cancer cells and in findings with potential clinical relevance.

    In summary, this webinar will demonstrate new ways of how MCTS-based HTS can be used to provide unique insights into context-dependent biology and cellular drug responses.

    About the Presenter:

    Wojciech Senkowski will soon complete his Ph.D. in Medical Sciences at Uppsala University, Sweden. In his work, he looks for applications of various tumor spheroid models in high throughput drug screening. For his work, Wojciech has received the AACR Scholar-in-Training Award. He was also a presenter and expert panelist at the Genetic Engineering & Biotechnology News webinar on 3D cell cultures, sponsored by Corning in February of 2016.
  • CiteScore metrics - now part of the Scopus basket of metrics
    CiteScore metrics - now part of the Scopus basket of metrics Norman Azoulay, Product Manager, Scopus and Chris James, Product Manager, Research Metrics Recorded: Jan 12 2017 51 mins
    Join us as we discuss CiteScore metrics - the free, transparent, comprehensive, and current metrics now available as part of the Scopus basket of metrics.

    Here are some of the topics you can expect to learn about:
    -The Scopus basket of metrics
    -Why have CiteScore metrics been added to the basket?
    -What are CiteScore metrics?
    -How can CiteScore metrics be accessed?
    -How you can get involved in defining the basket of metrics
    -Q&A
  • Automated Microscopy Data Comparison to Manual Microscopic Review
    Automated Microscopy Data Comparison to Manual Microscopic Review Dr. Michael Samoszuk Recorded: Jan 11 2017 26 mins
    In this webinar, Dr. Michael Samoszuk will discuss the correlation between images of urine sediment particles captured on the iRICELL3000 and images viewed manually under the microscope using actual patient samples. Attendees will learn how these images compare and how automated microscopy helps to reduce user subjectivity in microscopy by standardizing the process.
  • Achieve Better Hematology Quality Control with Bulls X̄B
    Achieve Better Hematology Quality Control with Bulls X̄B Dr. Guido Vranken and Lobke Tremmerie Recorded: Dec 13 2016 50 mins
    In this webinar, Dr. Guido Vranken and product manager Lobke Tremmerie discuss how to implement Bulls XB algorithm, which uses RBC indices to create a weighted moving average of patient sample results, to statistically monitor hematology results. This unique algorithm, offered on Beckman Coulter hematology instruments, allows users to monitor result quality with no additional reagents, software licenses or costs. Laboratories worldwide can implement this simple, powerful tool to enhance results and improve compliance. P.A.C.E. credit is available for your participation.*

    Dr. Guido Vranken has been working with customers for over 30 years across different disciplines, including protein chemistry, immunoassay and hematology. He specializes in conducting internal and external validation studies. Dr. Vranken spent three years as a lecturer on statistics at the University of Ghent.

    Lobke Tremmerie earned her environmental engineering degree from the University of Ghent in 2002. She first became an electrophoresis and nephelometry sales engineer at Analis, Beckman Coulter’s exclusive Belgian distributor. Following her true passion, she transferred into the hematology division in 2004. Ms. Tremmerie currently serves as Analis’ cellular biology product marketing manager.
  • Common Challenges to Overcome While Conducting BSL2 Studies
    Common Challenges to Overcome While Conducting BSL2 Studies Stephene Rose, MBM, James Justen, BS, Keith Nelson, PhD, DVM, DACVP,Joseph Hampel, DVM, DACLAM Recorded: Dec 8 2016 58 mins
    Preclinical laboratories face several challenges when conducting animal studies requiring Biosafety Level (BSL) 2 level containment. Some of these challenges include informed study design (including knowledge of associated regulatory guidelines), proper preparation of the vivarium, species isolation, traffic control between containment areas, training of personnel, veterinarian care, and proper decontamination of equipment/waste/bedding prior to disposal. In addition, proper post-life handling of animals and samples, with focused attention on tissue sampling and specialized evaluation is a vital element in ensuring personnel safety and high scientific quality. Overcoming these hurdles will generate high quality data and allow for a safe and productive environment.
  • Taking health wearables to the next level – where is the market heading?
    Taking health wearables to the next level – where is the market heading? Roberto Slepetys, Martin Pöhlchen, Gayatri Gopal, Andrew McConaghie Recorded: Dec 8 2016 63 mins
    With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
    In this webinar, experts from the life sciences and technology industries discuss their views on the current state and future developments of health wearables, including:
    – The user perspective: perception, adoption and expectations today and tomorrow
    – The technology perspective: biggest successes and most room for improvements
    – The societal and regulatory perspective: cost and risks versus benefits and opportunities
  • Adjusting Data Parameters to Improve Results and Workflow
    Adjusting Data Parameters to Improve Results and Workflow Dr. Michael Samoszuk Recorded: Dec 7 2016 18 mins
    In this webinar, Dr. Michael Samoszuk discusses the correlative relationships between urine chemistry analytes and the particles noted under the microscope. Attendees will learn how using the knowledge of these correlations can optimize parameter setting for improved laboratory workflow.
  • The Patient Centric Launch – business insights key to success in Europe
    The Patient Centric Launch – business insights key to success in Europe Nina Felton, Nick Cooper Larry R Smith II and Andrew McConaghie (moderator) Recorded: Nov 30 2016 61 mins
    Join us and PHOENIX group as we delve into the concept of current launch excellence and the role of patient insights in overcoming the multiple challenges the industry currently faces.
    Key topics to be discussed include:
    – The challenges of launching a product in Europe
    – How pharma can improve its understanding of the process through the use of business intelligence
    – How insights from new data can be applied to the process of launch excellence
    – The role of real-world data in launch strategy
    – The downstream effect of applying real-world data to product launch on patient outcomes.
  • The hepatitis C conundrum: balancing cost and affordability
    The hepatitis C conundrum: balancing cost and affordability Ashley Pitcher, Natasha Martin, Paul Tunnah Recorded: Nov 22 2016 68 mins
    Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.

    Key topics to be discussed include:
    – The burden of HCV
    – The current market landscape
    – The current patient access model and its impact on budget
    – Cost efficiencies shown by modelling
    – Cure versus lifetime treatment costs
  • Charting the digital heath information management transformation | Dell
    Charting the digital heath information management transformation | Dell Massimiliano Claps, Associate Vice President, IDC EMEA Health Insights Recorded: Nov 22 2016 24 mins
    Watch this Dell EMC and IDC Webcast, and explore integrated care readiness and how to sustain better decision making on care pathways as IDC shares results from its recent Health insights research.

    Learn more about the readiness of integrated care, the priorities of clinical and IT executives, the barriers still preventing having care truly centered around the patient. IDC health insights reports on the details of a research conducted in the UK and Nordics, measuring the maturity of adoption of strategies, governance and architectures able to sustain better decision making on care pathways. The webinar also includes a zoom into mental health integrated practices and directions, and addresses some of the most common mistakes and misconceptions on improving patient information management, including analyst's guidance for hospital, primary care and secondary care executives. 
  • 3 Ways to Retool Your Business with Technology in 2017
    3 Ways to Retool Your Business with Technology in 2017 Andrea Bradbury, Co-Founder and Chief Quality Officer, Suvoda Software; Jeinnfer Royer, Direct Product Marketing, DocuSign Apr 25 2017 8:00 pm UTC 60 mins
    Nearly 50% of business leaders fear they will become obsolete over the next several years, and nearly 80% feel threatened by digital startups. Why? New technologies and digital strategies are challenging existing business models and forcing companies of all sizes to reimagine patient care, product innovation and distribution models to remain competitive.

    View this on-demand webinar hosted by PharmaVOICE to learn from Andrea Bradbury, Co-Founder and Chief Quality Officer, Suvoda Software, a leader operating at the intersection of life sciences and technology as she shares how she built her business on a digital platform to accelerate her organization’s global expansion while meeting the needs of mobile, digital customers and employees.

    Topics covered include:

    - Streamlining clinical research, sales and HR processes with digital tools
    - Elevating the digital agenda at your organization
    - Scaling technologies globally
    - Applying nimble design models for life science operations
    - Implementing top life sciences trends in 2017
  • Life sciences promotional content management for speed, compliance and insight
    Life sciences promotional content management for speed, compliance and insight David Bennett, Andrew McConaghie Apr 27 2017 9:00 am UTC 75 mins
    The life sciences landscape is moving at a rapid pace, which in turn is increasing the demands on marketers to create innovative, digital content faster while maintaining industry compliance.

    Veeva Systems recently conducted an annual industry study, focused on content and digital asset management within life sciences. Gleaned from the experiences and opinions of leaders across the life sciences industry, the research uncovers current practices and the industry’s need for more advanced approaches for global marketing and regulatory compliance.

    Join this webinar to hear the key insights from the survey results, and discuss key highlights with host David Bennett, VP Commercial Content Strategy Europe, Veeva.

    From this webinar you will:

    – Learn the current state of commercial content and digital asset management in life sciences promotions
    – Garner an understanding of how your organization compares to the industry
    – Understand how to accelerate your content across the digital supply chain
  • Sample Preparation for Food Analysis:  New Technologies and Techniques
    Sample Preparation for Food Analysis: New Technologies and Techniques Jennifer Claus, Product Manager, Franchise Marketing Sample Preparation (Non-Bio) Apr 27 2017 1:00 pm UTC 75 mins
    In typical analytical workflows, sample preparation accounts for over 60% of the time taken to generate results and 30% of any errors generated. To help analytical chemists maintain the cornerstones of all analytical processes, namely; speed, specificity, sensitivity, and reproducibility, considerable resources have been devoted to the development of new and unique technologies in the sample preparation field. With specific reference to solid phase extraction and solid phase microextraction, this presentation will outline new technologies and techniques developed in sample preparation for food analysis.
  • The future of the clinical trial – collaboration and patient centricity
    The future of the clinical trial – collaboration and patient centricity Jameisha Brown, Eric Delente, Paulo Moreira, Christine Phillips, Andrew McConaghie May 3 2017 1:00 pm UTC 75 mins
    Growing patient influence combined with new technologies and the requirements of new reimbursement models means clinical research is undergoing rapid transformation. Industry is being compelled to move towards more patient centric solutions to keep up with these changes. With healthcare stakeholders in agreement that patient engagement is key to realising the value of clinical trials, regulators, sponsors, CROs, research funders and publishers are all moving towards more patient-focused models.

    With the advent of new methodologies, such as electronic data sources and medical records, recruiting patients for trials now demands extensive collaboration between patients and trial centers to effectively and efficiently run trials. The patient has never been more important.

    To mark Clinical Trials Awareness Week, pharmaphorum, in partnership with INC, will present a live webinar exploring the challenges and solutions of the current environment and how collaboration can benefit research participation, as well as the vital role the patient advocate plays in these matters.
  • Lung Cancer and IHC
    Lung Cancer and IHC Jeff Gordon, Cell Marque- Rocklin, CA May 12 2017 3:00 pm UTC 75 mins
    Lung cancer is the most commonly diagnosed non-skin cancer in the United States. Each year, over 222,000 people are diagnosed with lung cancer, and over 150,000 succumb each year to the illness, making it also the deadliest cancer in the country. With constant advancement of treatment options, the importance of accurate diagnosis and detection of lung cancer becomes more and more relevant to the survival of the patient. Immunohistochemistry has served as the catalyst for these advancements in lung cancer diagnosis. This presentation covers many of the basic science, facts, and statistics of lung cancer, as well as the utility of immunohistochemical testing with markers such as TTF-1, napsin A, desmoglein-3, and p40 in the accurate diagnosis and survival rates of lung cancer.
  • Basic Principles of Solid Phase Microextraction (SPME) Method Development
    Basic Principles of Solid Phase Microextraction (SPME) Method Development Emanuela Gionfriddo, Ph.D.; Research Associate under Prof. Janusz Pawliszyn, University of Waterloo (ON, Canada) May 31 2017 1:30 pm UTC 75 mins
    For the past two decades, Solid Phase Microextraction (SPME) has represented a convenient alternative to conventional sample prep procedures. SPME allows the simultaneous extraction and enrichment of analytes of interest from a given matrix in a single step while avoiding, or drastically minimizing, the use of organic solvents and time-consuming cleanup procedures.
    Like any other analytical method, the various parameters governing the SPME process need to be carefully optimized in order to achieve robustness and sensitivity. However, certain aspects of SPME method development are often overlooked by many users, leading to unsatisfactory performance of the technique.
    This webinar will shed light into several aspects of SPME method development. The presentation will include a theoretical explanation of SPME fundamentals and practical suggestions to overcome common errors and bias encountered when using SPME.
    The webinar is divided in three main sections: 1) optimization of extraction conditions 2) matrix modifications 3) optimization of desorption conditions for gas and liquid chromatography. Each section is divided in various subsections dedicated to each parameter affecting the performance of the SPME technique. The webinar attendees will be guided through comprehensive understanding of the technology and the critical parameters that influence the extraction process with practical examples from already existing methods.
  • Challenges in the Development of Continuous Processes for Vaccines
    Challenges in the Development of Continuous Processes for Vaccines Danny Vellom Jun 7 2017 2:00 pm UTC 75 mins
    The development and application of continuous manufacturing processes for vaccines presents both great opportunity as well as significant challenges, both technical and cultural, for the global industry. The key drivers are manufacturing capacity and flexibility, speed to market, and improved quality through the application of Quality-by-Design and Process Analytical Technology (QbD/PAT). Given the diversity of immunogens (toxoids, conjugate and subunit vaccines, live-attenuated and inactivated viruses, VLPs, etc.), and the variety of unique processes currently utilized to produce either single- or multi-component vaccines, it is unlikely that the transition to continuous processing will happen overnight. Additionally, cultural challenges are faced whenever a new mode of operation appears to some as “too different”, especially in a traditionally conservative sector like the developed-world vaccine industry. That said, market forces, global climate change, and Nature’s propensity to fill unoccupied niches with emerging infectious diseases will undoubtedly induce a first round of pioneers to explore this exciting new design space, ultimately leading to a more nimble industry and more and better opportunities for protection for the global population.
  • New Paradigm of Building Quality during Manufacture - Challenges with Biologics
    New Paradigm of Building Quality during Manufacture - Challenges with Biologics Dr Rajesh K. Gupta Aug 23 2017 2:00 pm UTC 75 mins
    Historically, quality of biological products has been ensured through testing representative samples. Shift in quality paradigm started with implementation of Good Manufacturing Practice (GMP) regulations with current focus on building quality during manufacture. Inherent variability and complexity of biological products pose challenges in implementing Quality by design (QbD) concept. This presentation discusses ways to build quality during manufacture of biological products.
  • Advances in Mass Spectrometry for the Analysis and Bioanalysis of Antibody-Drug
    Advances in Mass Spectrometry for the Analysis and Bioanalysis of Antibody-Drug Arnaud Delobel, PhD Sep 12 2017 2:00 pm UTC 75 mins
    ADCs are complex compounds resulting from the coupling of cytotoxic small molecules to a monoclonal antibody. Their characterization as well as their bioanalysis (quantification in biological fluids) remains challenging. Mass spectrometry at different levels (intact, middle, peptide) can be a valuable tool, and can now be used in a regulated environment thanks to advances in both hardware and software.
  • Can the New generation of perfusion technology compete or replace the convention
    Can the New generation of perfusion technology compete or replace the convention Ankur Bhatnagar Nov 15 2017 10:00 am UTC 75 mins
    Recently, there has been a renewed interest in the field of continuous processing. Some key factors driving this interest are – availability of better cell retention devices, improved cell lines and culture medium capable of supporting high cell densities.

    These factors have contributed mainly in reducing the batch duration for making the required quantity of product, thus reducing the medium requirement and chances of batch failures significantly. With the continuous processing being considered as ‘back-in-the-game’, the question remains: Can the current perfusion technology compete or replace the conventional and widely preferred fed-batch technology?

    Two cases are discussed to compare the performance features of fed-batch and perfusion processes. In both the cases, the product output from perfusion process is significantly higher (2 to 5 folds) than that from fed-batch, due to combination of factors like higher cell density, higher cell specific productivity, lower accumulation of toxic metabolites etc. These cases demonstrate the potential of perfusion process in significantly increasing the product output. However, there are certain challenges and points to be considered before a company decides to switch to a perfusion platform. Some of these are highlighted in the article.